Verrica Pharmaceuticals INC 8-K filings

Verrica Pharmaceuticals held its 2024 annual meeting where stockholders elected two directors, approved executive compensation on an advisory basis, and ratified the appointment of KPMG as the independent auditor.

Verrica Pharmaceuticals and Torii Pharmaceutical have amended their collaboration agreement to equally split the costs of a global Phase 3 clinical trial for YCANTH in the treatment of common warts.

Verrica Pharmaceuticals announced its first quarter 2024 financial results, highlighted by $3.2 million in revenue from YCANTH and progress in its clinical programs.

Verrica Pharmaceuticals announced its fourth quarter and full-year 2023 financial results, highlighted by $4.7 million in YCANTH revenue for the year and progress in its clinical pipeline.